AIM ImmunoTech Inc. (AIM) Institutional Ownership

Ownership Summary

Recent 13F filings as of December 2025 show that 13 institutional investors hold a position in AIM ImmunoTech Inc. (NYSE:AIM).

• Institutional ownership in AIM ImmunoTech edged down to 5.1% in December 2025, compared to 5.1% in September 2025.
• The company experienced a 35.29% quarterly change in institutional shares held, alongside a decrease of 63.89% in total owners annually.
• During the quarter, 7 institutions bought more AIM ImmunoTech shares, 0 sold shares, and 6 of the 13 total investors held their position steady.
• The aggregate institutional position in AIM ImmunoTech now stands at 105.98K shares as of December 2025, after investors increased their holdings (up by 27.65K shares quarter on quarter which is up 59.51K shares year over year).
• With 69.55K shares, DRW Securities, LLC commands the largest institutional position in AIM ImmunoTech as of December 31, 2025, equating to 3.32% of the company.
• Among the most significant buyers of AIM ImmunoTech during December 2025 were DRW Securities, LLC (26.25K), GEODE CAPITAL MANAGEMENT, LLC (1.19K), Tower Research Capital LLC (TRC) (125), UBS Group AG (75), BANK OF AMERICA CORP /DE/ (1).
• The top 10 institutional holders of AIM ImmunoTech for the quarter ending December 2025 included DRW Securities, LLC (69.55K), VANGUARD GROUP INC (17.50K), GEODE CAPITAL MANAGEMENT, LLC (17.38K), MORGAN STANLEY (864), UBS Group AG (379), Community Bank, N.A. (132), Tower Research Capital LLC (TRC) (125), BANK OF AMERICA CORP /DE/ (28), OSAIC HOLDINGS, INC. (15), HOEY INVESTMENTS, INC (10).